References
- American Cancer Society2007Cancer Facts and Figures 2007Georgia151
- BalducciLHardyCLLymanGH2000Hemopoietic reserve in the older cancer patient: clinical and economic considerationsCancer control75394711088062
- BalducciLBegheC2001Cancer and age in the USACrit Rev Oncol Hematol371374511166587
- BeerTPierceWCLoweBA2001Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancerAnn Oncol121273911697840
- BeerTMBerryWWersingerEM2003Weekly docetaxel in elderly patients with prostate cancer:efficacy and toxicity in patients at least 70 years of age compared with patients younger than 70Clin Prostate Cancer21677215040860
- BerryWRBeerTM2003Weekly docetaxel in the elderly, outcomes in men with androgen independent prostate cancer (AIPC)Proc Am Soc Clin Oncol22 (abstract 2996)
- BerryWRohrbaughT1999Phase II trial of single agent weekly Taxotere in symptomatic hormone refractory prostate cancerProc Am Soc Clin Oncol18335a (abstract 1290)
- EarhartRH1999Docetaxel (Taxotere): Preclinical and general clinical informationSem Oncol26813
- EisenbergerMABezerdjianLKalashS1988A critical assessment of the role of chemotherapy for endocrine resistant prostate carcinomaAUA Update Series721823
- EsmaeliBHidajiLAdininRB2003Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy cancerCancer98504712879466
- FossaSDAaronsonNKNewlingD1990Advanced hormone resistant prostate cancer:preliminary observation on subjective morbidity and palliationEur Urol18 2 abstract
- GokerERodenhuisS2005Early onset of oral aphthous ulcers with weekly docetaxelNeth J Med63364616244385
- HaldarSBasuACroceCM1997Bcl2 is the guardian of microtubule integrityCancer Res57229339000560
- HudesGGreenbergRKriegelR1992Phase II study of estramustine and vinblastine, two microtubular inhibitors, in hormone refractory prostate cancerJ Clin Oncol101754611383436
- HyattMJHowladerNReichmanME2007Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) ProgramThe Oncologist12203717227898
- JemelASiegelRWardE2007Cancer statistics 2007CA Cancer J Clin57436617237035
- KantoffPWHalabSConawayM1999Hydrocortisone with or without mitoxantrone in patients with hormone refractory prostate cancer: Results of cancer and leukemia group BJ Clin Oncol1725061310561316
- KrausLASamuelSKSchmidSM2003The mechanism of action of docetaxel (Taxotere) in xenograph models is not limited to Bcl-2-2phosphorylationInvest New Drugs212596814578676
- KreisWBudmanD1999Daily oral estramustine and intermittent intravenous docetaxel (Taxotere) as chemotherapeutic treatment for metastatic, hormone-refractory prostate cancerSemin Oncol2634810604267
- PetrylakDPMacArthurRBO’ConnorJ1999Phase I trial of docetaxel and estramustine in androgen independent prostate cancerJ Clin Oncol179586710071290
- PetrylakDPTangenCMHusseinMHA2004Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancerN Engl J Med35115132015470214
- PicusJSchultzMCochraneJ1999A phase II trial of docetaxel in patients with hormone refractory prostate cancer (HRPC):long term resultsProc Am Soc Clin Oncol18314a abstract 11206
- SavareseDTaplinMEHalabiS1999A phase II study of docetaxel (Taxotere), estramustine and low-dose hydrocortisone in men with hormone refractory prostate:preliminary results of cancer and leukemia group B trial 9780Sem Oncol263944
- SinibaldiVJSCarducciMAMoore-CooperS2002Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate cancerCancer9414576511920502
- SteinCA1999Mechanism of action of taxanes in prostate cancerSemin Oncol263710604261
- TannockIFde WitRBerryWR2004Docetaxel plus prednisone or mitoxantrone for advanced prostate cancerN Engl J Med35115021215470213
- TannockIFOsobaDShocklerMR1996Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone resistant prostate cancer:a Canadian randomized trial with palliative endpointsJ Clin Oncol141756648656243
- Taxotere Prescribing Information [package insert]32006Bridgewater, NJ Sanofi-AventisUS LLC
- United Nations2007The aging of the world’s populationPopulation Division, Department of Economic and Social Affairs, United Nations Secretariat
- YancikRRiesLA2004Cancer in older persons:magnitude of problem – How do we apply what we know?Cancer74199520038087762